Gary Bird Appointed CEO of LumaCina

LumaCina, a global supplier and marketer of sterile injectable pharmaceutical products and a Bridgewest Group portfolio company, announced the appointment of Gary Bird as Chief Executive Officer, effective immediately. Bird's appointment is expected to accelerate the company's growth and expand its global portfolio of sterile injectables.

Executive Chair Mark Crotty, who appointed Bird, will continue to lead LumaCina's long-term strategy and oversee platform development. Bird's role will focus on the company's day-to-day operations and its next phase of expansion, working in close partnership with Crotty.

Bird brings over three decades of leadership experience within the Australian pharmaceutical industry, specializing in commercial strategy, market expansion, and partnership-led growth. His career includes leadership roles at companies such as Orion Pharma, Medreich, Meda, Johnson & Johnson, Sanofi-Aventis, and Pharmacia.

"What attracted me to LumaCina is the company's values, the quality of its people and the opportunity to establish LumaCina as a global pharmaceutical company," said Gary Bird. "LumaCina is well positioned to meet the increasing reliance of healthcare systems on trusted partners for high-quality essential medicines."

Bird has already engaged with LumaCina's leadership team, gaining insights into the business, its customers, and strategic priorities. The company supplies sterile injectable drugs manufactured in Perth, Australia, to customers across Australia, New Zealand, Asia, and Northern Europe.